Junbiao Tian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junbiao Tian has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Feng Wang
Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine Cangzhou China
1 shared publication- Huantian Cui
First School of Clinical Medicine Yunnan University of Chinese Medicine Kunming China
1 shared publication Jian Wang
Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine Cangzhou China
1 shared publicationJianwen Zhao
Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine Cangzhou China
1 shared publication- Jiayun Zhang
School of Chemistry and Molecular Biosciences
1 shared publication - Li-Min Zhang
Hebei Province Key Laboratory of Integrated Traditional and Western Medicine in Neurological Rehabilitation, Cangzhou, China
1 shared publication
Latest Publications
- Open Access
- 24 February 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (4) , e70340
Mechanism of Formononetin in Improving Energy Metabolism and Alleviating Neuronal Injury in CIRI Based on Nontargeted Metabolomics Research
Cerebral ischaemia–reperfusion injury (CIRI), resulting from thrombolytic therapy for ischaemic stroke, presents a considerable challenge during postoperative recovery. Formononetin (FMN) has shown promise in the prevention and treatment of neurological diseases. However, its specific mechanism in ameliorating CIRI remains uncertain. Initially, we established a CIRI rat model to evaluate FMN's therapeutic potential by assessing neurological function, infarct area and pathological changes. Subsequently, we employed metabolomics technology to investigate FMN's impact on metabolite levels in the ischaemic brain tissue of CIRI rats. Based on the metabolomics findings, we validated FMN's effects on nicotinate and nicotinamide metabolism, as well as alanine, aspartate and glutamate metabolism, along with its influence on neuronal injury and repair. Our investigation unveiled that FMN intervention significantly diminished the Longa score and asymmetry score in CIRI rats, constricted the infarct area and ameliorated pathological alterations in the ischaemic brain tissue, including reduced DCI index and augmented Nissl body count. Metabolomics analysis indicated that FMN exerted regulatory effects on nicotinate and nicotinamide metabolism, as well as alanine, aspartate and glutamate metabolism. Following FMN intervention, there was a notable increase in the levels of related metabolites such as nicotinamide (NAM), L‐aspartic acid (L‐Asp), fumaric acid (FA), gamma‐aminobutyric acid (GABA) and L‐glutamic acid (L‐Glu). RT‐qPCR and Western blot outcomes demonstrated that FMN upregulated the gene and protein expression of key enzymes adenylosuccinate lyase (ADSL) and glutamic acid decarboxylase (GAD) involved in alanine, aspartate and glutamate metabolism. Moreover, FMN intervention bolstered SOD activity, diminished MDA and ROS levels and reduced TUNEL‐positive expression. Furthermore, FMN intervention elevated ATP levels and markedly increased Ki67‐positive expression. FMN exhibits the potential to alleviate oxidative stress injury in CIRI rats by enhancing nicotinate and nicotinamide metabolism along with alanine, aspartate and glutamate metabolism, consequently reinstating energy metabolism and conferring neuroprotective effects to ameliorate CIRI.
- 24 February 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (4) , e70340
Open AccessMechanism of Formononetin in Improving Energy Metabolism and Alleviating Neuronal Injury in CIRI Based on Nontargeted Metabolomics Research
Cerebral ischaemia–reperfusion injury (CIRI), resulting from thrombolytic therapy for ischaemic stroke, presents a considerable challenge during postoperative recovery. Formononetin (FMN) has shown promise in the prevention and treatment of neurological diseases. However, its specific mechanism in ameliorating CIRI remains uncertain. Initially, we established a CIRI rat model to evaluate FMN's therapeutic potential by assessing neurological function, infarct area and pathological changes. Subsequently, we employed metabolomics technology to investigate FMN's impact on metabolite levels in the ischaemic brain tissue of CIRI rats. Based on the metabolomics findings, we validated FMN's effects on nicotinate and nicotinamide metabolism, as well as alanine, aspartate and glutamate metabolism, along with its influence on neuronal injury and repair. Our investigation unveiled that FMN intervention significantly diminished the Longa score and asymmetry score in CIRI rats, constricted the infarct area and ameliorated pathological alterations in the ischaemic brain tissue, including reduced DCI index and augmented Nissl body count. Metabolomics analysis indicated that FMN exerted regulatory effects on nicotinate and nicotinamide metabolism, as well as alanine, aspartate and glutamate metabolism. Following FMN intervention, there was a notable increase in the levels of related metabolites such as nicotinamide (NAM), L‐aspartic acid (L‐Asp), fumaric acid (FA), gamma‐aminobutyric acid (GABA) and L‐glutamic acid (L‐Glu). RT‐qPCR and Western blot outcomes demonstrated that FMN upregulated the gene and protein expression of key enzymes adenylosuccinate lyase (ADSL) and glutamic acid decarboxylase (GAD) involved in alanine, aspartate and glutamate metabolism. Moreover, FMN intervention bolstered SOD activity, diminished MDA and ROS levels and reduced TUNEL‐positive expression. Furthermore, FMN intervention elevated ATP levels and markedly increased Ki67‐positive expression. FMN exhibits the potential to alleviate oxidative stress injury in CIRI rats by enhancing nicotinate and nicotinamide metabolism along with alanine, aspartate and glutamate metabolism, consequently reinstating energy metabolism and conferring neuroprotective effects to ameliorate CIRI.
- Open Access
- 2 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Association between the systemic immunity-inflammation index and stroke: a population-based study from NHANES (2015–2020)
Background The systemic immunity-inflammation index(SII) is a new indicator of composite inflammatory response. Inflammatory response is an important pathological process in stroke. Therefore, this study sought to investigate the association between SII and stroke. Methods We collected data on participants with SII and stroke from the 2015–2020 cycle of National Health and Nutrition Examination Survey (NHANES) for the cross-sectional investigation. Multivariate linear regression models were used to test the association between SII and stroke. Fitted smoothing curves and threshold effect analysis were applied to describe the nonlinear relationship. Results A total of 13,287 participants were included in our study, including 611 (4.598%) participants with stroke. In a multivariate linear regression analysis, we found a significant positive association between SII and stroke, and the odds ratio (OR) [95% CI] of SII associating with prevalence of stroke was [1.02 (1.01, 1.04)] (P < 0.01). In subgroup analysis and interaction experiments, we found that this positive relationship was not significantly correlated among different population settings such as age, gender, race, education level, smoking status, high blood pressure, diabetes and coronary heart disease (P for trend > 0.05). Moreover, we found an nonlinear relationship between SII and stroke with an inflection point of 740 (1,000 cells /µl) by using a two-segment linear regression model. Conclusions This study implies that increased SII levels are linked to stroke. To confirm our findings, more large-scale prospective investigations are needed.
- 2 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Open AccessAssociation between the systemic immunity-inflammation index and stroke: a population-based study from NHANES (2015–2020)
Background The systemic immunity-inflammation index(SII) is a new indicator of composite inflammatory response. Inflammatory response is an important pathological process in stroke. Therefore, this study sought to investigate the association between SII and stroke. Methods We collected data on participants with SII and stroke from the 2015–2020 cycle of National Health and Nutrition Examination Survey (NHANES) for the cross-sectional investigation. Multivariate linear regression models were used to test the association between SII and stroke. Fitted smoothing curves and threshold effect analysis were applied to describe the nonlinear relationship. Results A total of 13,287 participants were included in our study, including 611 (4.598%) participants with stroke. In a multivariate linear regression analysis, we found a significant positive association between SII and stroke, and the odds ratio (OR) [95% CI] of SII associating with prevalence of stroke was [1.02 (1.01, 1.04)] (P < 0.01). In subgroup analysis and interaction experiments, we found that this positive relationship was not significantly correlated among different population settings such as age, gender, race, education level, smoking status, high blood pressure, diabetes and coronary heart disease (P for trend > 0.05). Moreover, we found an nonlinear relationship between SII and stroke with an inflection point of 740 (1,000 cells /µl) by using a two-segment linear regression model. Conclusions This study implies that increased SII levels are linked to stroke. To confirm our findings, more large-scale prospective investigations are needed.